Globenewswire·2025-11-03 13:00Core Insights - Orchestra BioMed Holdings, Inc. is set to host a business update call on November 12, 2025, focusing on significant clinical, strategic, and financing developments [1][2] Company Developments - The update will cover a strategic investment and collaboration expansion with Medtronic, a new capital relationship with Ligand, and a right of first refusal agreement with Terumo [2] - Enrollment in the BACKBEAT pivotal study of AVIM Therapy is accelerating, and patient enrollment has begun in the Virtue SAB US pivotal IDE coronary trial [2] Product Information - Orchestra BioMed's flagship products include Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB), both undergoing pivotal clinical trials [3] - AVIM Therapy targets uncontrolled hypertension and has FDA Breakthrough Device Designation, with an estimated 7.7 million patients in the U.S. affected [3] - Virtue SAB is a drug delivery angioplasty balloon system designed for treating atherosclerotic artery disease and has also received FDA Breakthrough Device Designation [3]